This is a modular study of AZD2014 in combination with novel anti-cancer agents in patients
with different subtypes of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Module 1, a combination with ibrutinib in patients with non-germinal centre B-cell-like
(non-GCB) DLBCL, will consist of Part A, a Phase I dose-finding arm in which the safety and
tolerability of the combination will be assessed, and Part B, a Phase II dose-expansion phase
to assess the efficacy of the combination.